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The performance of a microarray for the detection of extended-spectrum beta-lactamases was determined on
a collection of 638 highly resistant members of the family Enterobacteriaceae collected from patients in 18
hospitals in The Netherlands. The microarray had a significantly higher specificity than the phenotypic assays.
It also detects carbapenemases and characterizes the resistance genes, providing epidemiological insight.
The worldwide prevalence of extended-spectrum beta-lacta-
mase-producing members of Enterobacteriaceae (ESBL-E) is
increasing rapidly (1). Controlling ESBL-E is difficult, as the
resistance genes are located on plasmids and may be trans-
ferred between species and even different genera of the Entero-
bacteriaceae family (10). The rapid laboratory detection of this
resistance trait is important to guide antimicrobial therapy and
to take appropriate infection control measures.
We evaluated a ligation-mediated amplification in combina-
tion with a microarray to detect and characterize ESBL-E in a
contemporary collection of Enterobacteriaceae from a repre-
sentative sample of hospitals in The Netherlands.
Multicenter prospective surveillance was performed in 18
Dutch hospitals during 6 months in 2007. All newly identified
patients with highly resistant members of the family Entero-
bacteriaceae were included. The criteria for highly resistant
Enterobacteriaceae are defined in the Dutch national guideline
for the control of highly resistant microorganisms (6).
Susceptibility tests were interpreted according to Clinical
and Laboratory Standards Institute (CLSI) guidelines (2).
ESBL production was determined as previously described (9).
All Escherichia coli, Klebsiella spp., Proteus mirabilis, Salmo-
nella spp., and Shigella spp. (group I) were tested with ceftaz-
idime and cefotaxime with and without clavulanic acid. All
Enterobacter spp., Serratia spp., Providencia spp., Citrobacter
freundii, Morganella morganii, and Hafnia alvei (group II) were
tested with cefepime with and without clavulanic acid (12).
When Etest results were not conclusive, a disk diffusion test
(Roscodiagnostica, Taastrup, Denmark) was performed with
the double-disk methodology, using a similar algorithm.
DNA isolation was performed with the Easymaq system
(bioMe´rieux, Marcy l’Etoile, France) according to the manu-
facturer’s instructions. The Check-KPC ESBL array (Check-
Points, Wageningen, The Netherlands) was used as previously
described (12). blaSHV, blaTEM, and blaCTX-M genes were am-
plified by PCR (3). Sequence analysis and alignments were
performed with the Bionumerics 6.01 software program (Ap-
plied Maths, Sint-Martens-Latem, Belgium), BLAST program
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), and information from
the www.lahey.org/studies website.
All isolates with concordant phenotypic and genotypic ESBL
detection results were considered identified correctly. For dis-
cordant findings, the results of sequencing were considered the
gold standard.
A total of 638 highly resistant members of the family Entero-
bacteriaceae were included (Table 1). On the basis of the phe-
notypic test results, 355 (55.6%) isolates were considered
ESBL producers. The microarray detected one or more ESBL
genes in 345 of the 638 (54.1%) isolates.
The overall phenotypic and genotypic results for 590 out of
638 (92.5%) isolates were concordant. In group I, the majority
(24/30) of discordant results had a positive phenotypic test and
a negative microarray result. In group II, the majority (12/18)
had a negative phenotypic test and a positive microarray result.
Table 2 shows the performance of the phenotypic and mi-
croarray tests when the results of sequencing are incorporated
into the gold standard. For group I, the sensitivities were com-
parable, but the microarray was more specific. For group II,
the microarray was more sensitive, and the specificities were
comparable.
Seven of the false-positive phenotypic tests were negative
upon retesting, and six of the false-negative test results were
positive. Also, both false-positive microarray results were neg-
ative upon retesting and five false-negative microarray results
were positive on retesting. In Table S1 in the supplemental
material, all discordant findings are shown.
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The 345 isolates that produced ESBLs according to the
microarray had various types of ESBL genes (Table 3). More
than half of the group I isolates from the Enterobacteriaceae
had blaCTX-M-1 family ESBL genes, whereas in group II, the
blaCTX-M-1 family of ESBL genes constituted a minority of
the genes. The most prevalent ESBL type in group II was the
blaCTX-M-9 family (61.6%). Some isolates contained more than
one ESBL gene. blaTEM coexisted once with a blaCTX-M-1 fam-
ily ESBL gene and once with a blaCTX-M-9 family gene both in
group I organisms. blaSHV was found six times in combination
with blaCTX-M-1 family in group I organisms and nine times in
combination with the blaCTX-M-9 family in group I (n  7) and
group II (n  2) organisms. One K. oxytoca isolate contained
three different genes (blaTEM, blaSHV, and blaCTX-M-9 family).
In addition to ESBL genes, the microarray detects carbap-
enemase genes: these genes were detected in two Klebsiella
pneumoniae isolates, both from the same patient. This patient
who had been hospitalized in Greece after a traffic accident
was subsequently transferred to a general hospital in The
Netherlands and from there to a university hospital. Both hos-
pitals in The Netherlands participated in our survey. Resis-
tance to carbapenems had not been detected in the diagnostic
laboratory with the standard laboratory procedures but was
confirmed upon retesting. The Etest MIC for ertapenem was
24.0 mg/ml.
This evaluation showed that the diagnostic microarray was
more accurate than the current phenotypic methods to detect
ESBL genes in a representative sample of clinical isolates. This
microarray has recently been evaluated on three collections of
selected isolates containing the majority of known ESBL and
KPC genes (3, 5, 7). In the first evaluation (3), it detected 95%
of the isolates that contained an ESBL gene and did not pro-
duce false-positive results. The second evaluation (7) included
a well-defined collection of ESBL and KPC producers and
confirmed the ability of the array to detect most resistance
genes. In one case, the array failed to detect a KPC gene, but
the authors concluded that plasmid instability was the most
likely explanation for this negative result. The third study
tested the array on 106 Gram-negative strains (5). The follow-
ing sensitivities and specificities, respectively, were recorded:
98.8% and 100% for blaSHV, 100% and 96.4% for blaTEM, and
100% and 100% for blaCTX-M and blaKPC. These promising
results from the analytic evaluations were confirmed in our
study. The false-positive phenotypic tests observed in group I
were often negative upon retesting. This reflects the subjectiv-
ity involved with the interpretation of the results. In group II,
chromosomal AmpC production is a known pitfall for the
phenotypic methods, resulting in a substantially reduced spec-
ificity (11). As we did not include all known ESBL genes in the
sequencing reactions, there is a possibility that some of the
TABLE 1. Distribution of bacterial species
Group and species No. of isolates (%)
Group I (n  501)
Escherichia coli .................................................................332 (66.3)
Klebsiella pneumoniae ...................................................... 93 (18.6)
Proteus mirabilis ................................................................ 41 (8.2)
Klebsiella oxytoca .............................................................. 29 (5.8)
Salmonella spp. ................................................................. 3 (0.6)
Shigella spp........................................................................ 2 (0.4)
Pantoea spp. ...................................................................... 1 (0.2)
Group II (n  137)
Enterobacter cloacae ......................................................... 87 (63.5)
Citrobacter freundii ........................................................... 24 (17.5)
Morganella morganii ......................................................... 9 (6.6)
Serratia marcescens ........................................................... 6 (4.4)
Citrobacter spp. ................................................................. 6 (4.4)
Enterobacter aerogenes...................................................... 3 (2.2)
Providencia spp. ................................................................ 2 (1.5)
TABLE 2. Results of the phenotypic tests and microarray testing
after resolution of discordant resultsa
Test, group, and
isolates
No. of results Total no.
of resultsESBL-negative ESBL-positive
Phenotypic tests
Group I
ESBL negative 205 5 210
ESBL positive 16 275 291
Total 221 280 501
Group II
ESBL negative 61 11 72
ESBL positive 5 59 64
Inconclusive 0 1 1
Total 66 71 137
Microarray
Group I
ESBL negative 220 8 228
ESBL positive 1 272 273
Total 221 280 501
Group II
ESBL negative 65 0 65
ESBL positive 1 71 72
Total 66 71 137
a The performance of the phenotypic and microarray test when the results of
sequencing are incorporated into the gold standard. For phenotypic tests on
group I, the sensitivity was 98.2%, and the specificity was 92.8%. For phenotypic
tests on group II, the sensitivity was 83.1%, and the specificity was 92.4%. For the
microarray on group I, the sensitivity was 97.2%, and the specificity was 99.5%.
In group I, the specificity of the microarray was statistically significantly higher
than that of the phenotypic test (P  0.001). For the microarray on group II, the
sensitivity was 100%, and the specificity was 99.5%. In group II, the sensitivity of
the microarray was statistically significantly higher than that of the phenotypic
test (P  0.001).
TABLE 3. Identification of extended-spectrum beta-lactamase
genes of group I and group II isolates in
Enterobacteriaceae by microarray
ESBL gene type
No. of genes (%) Total no. of
genes (%)Group I Group II
TEM 27 (9.5) 3 (3.8) 30 (8.2)
SHV 47 (16.5) 20 (25.3) 67 (18.4)
CTX-M-1 153 (53.7)a 6 (7.6)a 159 (43.7)
CTX-M-2 0 (0) 4 (5.1) 4 (1.1)
CTX-M-9 58 (20.4)a 45 (57.0)a 103 (28.3)
CTX-M-8/M-25 0 (0) 1 (1.3) 1 (0.3)
Total 285 (100) 79 (100) 364 (100)
a The differences between the values for group I and group II are statistically
significant for CTX-M-1 and CTX-M-9.
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false-positive phenotypic test results are in fact true-positive
results that were not detected by the molecular tests. However,
the ESBL genes that were not included are rare. In conclusion,
there were only a few failures of the array to detect ESBL
genes, and the specificity of the microarray was superior to the
phenotypic tests, which makes this commercially available mi-
croarray a highly reliable tool to detect and identify ESBL
genes in the clinical setting. In addition, it also detects the
presence of carbapenemase genes, which are nowadays con-
sidered to be the most important threats of antimicrobial re-
sistance (8). Finally, the array identifies the type of ESBL that
is present, as shown in Table 3. The epidemiology of ESBL-E
is rapidly changing, and it is poorly understood how the resis-
tance genes are spreading and which reservoirs are involved
(4). This new tool will likely improve insight into the epidemi-
ology of resistance genes, which may be an aid in the further
control of resistance.
Check-Points BV, Wageningen, The Netherlands, supplied the ma-
terials for the microarray.
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